Peggy Scherle - Prelude Therapeutics Chief Officer
| PRLD Stock | USD 1.05 0.07 7.14% |
Insider
Peggy Scherle is Chief Officer of Prelude Therapeutics
| Age | 62 |
| Address | 175 Innovation Boulevard, Wilmington, DE, United States, 19805 |
| Phone | 302 467 1280 |
| Web | https://preludetx.com |
Prelude Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3929) % which means that it has lost $0.3929 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6664) %, meaning that it created substantial loss on money invested by shareholders. Prelude Therapeutics' management efficiency ratios could be used to measure how well Prelude Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 30, 2024, Return On Tangible Assets is expected to decline to -0.46. In addition to that, Return On Capital Employed is expected to decline to -0.54. At present, Prelude Therapeutics' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 11.4 M, whereas Net Tangible Assets are forecasted to decline to about 136.7 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Kelly Schick | C4 Therapeutics | 44 | |
| Josh Eizen | AN2 Therapeutics | N/A | |
| Michael Todisco | Kymera Therapeutics | 59 | |
| Allan MD | Foghorn Therapeutics | 49 | |
| Gerald Md | Foghorn Therapeutics | N/A | |
| Jared MD | Kymera Therapeutics | 59 | |
| David Pompliano | Revolution Medicines | N/A | |
| Vijay Sabesan | Kymera Therapeutics | 52 | |
| , MBA | Molecular Partners AG | 51 | |
| John Kuriyan | Nurix Therapeutics | N/A | |
| Brian MD | Rezolute | 49 | |
| Michael Gait | PepGen | N/A | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
| Abhinav Shukla | Shattuck Labs | ||
| Jochen Knolle | Pharvaris BV | 74 | |
| Conor Richardson | Shattuck Labs | N/A | |
| MBA BS | AN2 Therapeutics | 49 | |
| JD Esq | Nurix Therapeutics | 63 | |
| MSc MBA | Passage Bio | 55 | |
| Michael Pitzner | Molecular Partners AG | N/A | |
| MD MBA | Rezolute | N/A | |
Management Performance
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.39 |
Prelude Therapeutics Leadership Team
Elected by the shareholders, the Prelude Therapeutics' board of directors comprises two types of representatives: Prelude Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Prelude. The board's role is to monitor Prelude Therapeutics' management team and ensure that shareholders' interests are well served. Prelude Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Prelude Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Laurent MBA, Chief Officer | ||
| Edna MD, President Officer | ||
| William MD, Senior Development | ||
| Naveen Babbar, Senior Medicine | ||
| Neelesh MD, VP Devel | ||
| Aimee Crombie, Senior Operations | ||
| Madhu Pudipeddi, Senior Operations | ||
| Lindsey Trickett, Vice Relations | ||
| Michele MBA, Chief Officer | ||
| Krishna DVM, CEO Founder | ||
| Peggy Scherle, Chief Officer | ||
| Laurent Chardonnet, Chief Officer | ||
| Bryant JD, Chief Secretary | ||
| Andrew Combs, Executive Chemistry |
Prelude Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Prelude Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.39 | ||||
| Operating Margin | (11.46) % | ||||
| Current Valuation | (77.7 M) | ||||
| Shares Outstanding | 42.18 M | ||||
| Shares Owned By Insiders | 9.06 % | ||||
| Shares Owned By Institutions | 85.00 % | ||||
| Number Of Shares Shorted | 2.9 M | ||||
| Price To Book | 0.37 X | ||||
| Price To Sales | 19.26 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Prelude Therapeutics is a strong investment it is important to analyze Prelude Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Prelude Therapeutics' future performance. For an informed investment choice regarding Prelude Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Prelude Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Prelude Therapeutics. If investors know Prelude will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Prelude Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.77) | Revenue Per Share 0.04 | Return On Assets (0.39) | Return On Equity (0.67) |
The market value of Prelude Therapeutics is measured differently than its book value, which is the value of Prelude that is recorded on the company's balance sheet. Investors also form their own opinion of Prelude Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Prelude Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Prelude Therapeutics' market value can be influenced by many factors that don't directly affect Prelude Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Prelude Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Prelude Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Prelude Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.